BACKGROUND: Poly(ADP-ribose) polymerase (PARP)-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the effect of combined therapy against PARP and angiogenesis in this population has not been reported. We investigated the toxicities and recommended phase 2 dosing (RP2D) of the combination of cediranib, a multitargeted inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3 and olaparib, a PARP-inhibitor (NCT01116648). METHODS: Cediranib tablets once daily and olaparib capsules twice daily were administered orally in a standard 3+3 dose escalation design. Patients with recurrent ovarian or metastatic triple-negative breast cancer were eligible. Patients had measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or met Gynecologic Cancer InterGroup (GCIG) CA125 criteria. No prior PARP-inhibitors or anti-angiogenics in the recurrent setting were allowed. RESULTS: 28 patients (20 ovarian, 8 breast) enrolled to 4 dose levels. 2 dose limiting toxicities (DLTs) (1 grade 4 neutropenia ≥ 4 days; 1 grade 4 thrombocytopenia) occurred at the highest dose level (cediranib 30 mg daily; olaparib 400 mg twice daily [BID]). The RP2D was cediranib 30 mg daily and olaparib 200 mg BID. Grade 3 or higher toxicities occurred in 75% of patients, and included grade 3 hypertension (25%) and grade 3 fatigue (18%). One grade 3 bowel obstruction occurred. The overall response rate (ORR) in the 18 RECIST-evaluable ovarian cancer patients was 44%, with a clinical benefit rate (ORR plus stable disease (SD) > 24 weeks) of 61%. None of the seven evaluable breast cancer patients achieved clinical response; two patients had stable disease for > 24 weeks. INTERPRETATION: The combination of cediranib and olaparib has haematologic DLTs and anticipated class toxicities, with promising evidence of activity in ovarian cancer patients.
BACKGROUND:Poly(ADP-ribose) polymerase (PARP)-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the effect of combined therapy against PARP and angiogenesis in this population has not been reported. We investigated the toxicities and recommended phase 2 dosing (RP2D) of the combination of cediranib, a multitargeted inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3 and olaparib, a PARP-inhibitor (NCT01116648). METHODS:Cediranib tablets once daily and olaparib capsules twice daily were administered orally in a standard 3+3 dose escalation design. Patients with recurrent ovarian or metastatic triple-negative breast cancer were eligible. Patients had measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or met Gynecologic Cancer InterGroup (GCIG) CA125 criteria. No prior PARP-inhibitors or anti-angiogenics in the recurrent setting were allowed. RESULTS: 28 patients (20 ovarian, 8 breast) enrolled to 4 dose levels. 2 dose limiting toxicities (DLTs) (1 grade 4 neutropenia ≥ 4 days; 1 grade 4 thrombocytopenia) occurred at the highest dose level (cediranib 30 mg daily; olaparib 400 mg twice daily [BID]). The RP2D was cediranib 30 mg daily and olaparib 200 mg BID. Grade 3 or higher toxicities occurred in 75% of patients, and included grade 3 hypertension (25%) and grade 3 fatigue (18%). One grade 3 bowel obstruction occurred. The overall response rate (ORR) in the 18 RECIST-evaluable ovarian cancerpatients was 44%, with a clinical benefit rate (ORR plus stable disease (SD) > 24 weeks) of 61%. None of the seven evaluable breast cancerpatients achieved clinical response; two patients had stable disease for > 24 weeks. INTERPRETATION: The combination of cediranib and olaparib has haematologic DLTs and anticipated class toxicities, with promising evidence of activity in ovarian cancerpatients.
Authors: Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza Journal: Lancet Oncol Date: 2011-08-19 Impact factor: 41.316
Authors: M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan Powell; Katherine M Bell-McGuinn; Clare Scott; Jeffrey N Weitzel; Ana Oaknin; Niklas Loman; Karen Lu; Rita K Schmutzler; Ursula Matulonis; Mark Wickens; Andrew Tutt Journal: Lancet Date: 2010-07-06 Impact factor: 79.321
Authors: Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael Journal: Lancet Date: 2010-07-06 Impact factor: 79.321
Authors: Denise Campisi Hegan; Yuhong Lu; Gregory C Stachelek; Meredith E Crosby; Ranjit S Bindra; Peter M Glazer Journal: Proc Natl Acad Sci U S A Date: 2010-01-19 Impact factor: 11.205
Authors: Ursula A Matulonis; Suzanne Berlin; Percy Ivy; Karin Tyburski; Carolyn Krasner; Corrine Zarwan; Anna Berkenblit; Susana Campos; Neil Horowitz; Stephen A Cannistra; Hang Lee; Julie Lee; Maria Roche; Margaret Hill; Christin Whalen; Laura Sullivan; Chau Tran; Benjamin D Humphreys; Richard T Penson Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Ranjit S Bindra; Paul J Schaffer; Alice Meng; Jennifer Woo; Kårstein Måseide; Matt E Roth; Paul Lizardi; David W Hedley; Robert G Bristow; Peter M Glazer Journal: Mol Cell Biol Date: 2004-10 Impact factor: 4.272
Authors: E Dean; M R Middleton; T Pwint; H Swaisland; J Carmichael; P Goodege-Kunwar; M Ranson Journal: Br J Cancer Date: 2012-01-05 Impact factor: 7.640
Authors: Peng Guo; Jing Huang; Liya Wang; Di Jia; Jiang Yang; Deborah A Dillon; David Zurakowski; Hui Mao; Marsha A Moses; Debra T Auguste Journal: Proc Natl Acad Sci U S A Date: 2014-09-29 Impact factor: 11.205
Authors: Cody J Peer; Jung-Min Lee; Jeffrey Roth; Louis Rodgers; Jeffers Nguyen; Christina M Annunziata; Lori Minasian; Elise C Kohn; William D Figg Journal: Cancer Chemother Pharmacol Date: 2017-06-02 Impact factor: 3.333
Authors: Ilary Ruscito; Maria Luisa Gasparri; Claudia Marchetti; Caterina De Medici; Carlotta Bracchi; Innocenza Palaia; Sara Imboden; Michael D Mueller; Andrea Papadia; Ludovico Muzii; Pierluigi Benedetti Panici Journal: Tumour Biol Date: 2016-01-11
Authors: Yiduo Hu; Sarah A Petit; Scott B Ficarro; Kimberly J Toomire; Anyong Xie; Elgene Lim; Shiliang A Cao; Eunyoung Park; Michael J Eck; Ralph Scully; Myles Brown; Jarrod A Marto; David M Livingston Journal: Cancer Discov Date: 2014-09-24 Impact factor: 39.397
Authors: Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby Journal: Cancer Prev Res (Phila) Date: 2014-05-09